Course Description: Exposes students to the business of biotech from scientific discovery startup through its product launch and subsequent organizational and scientific pipeline growth. Topics include scientific discovery, biotech-related funding and organizational structures, regulatory and clinical trial considerations, biotech alliances, patient access, ethics and compliance, and commercialization and growth while meeting unmet patient or consumer needs in this highly regulated industry. Although the focus is on the highest regulated standards in biopharma, the course also touches upon various aspects of other biotechnology domains.
Course Info and Faculty Bio(s)
NOTE – THERE ARE FOUR SECTIONS OF THIS COURSE PARTICIPATING IN THE SOCIAL CHANGE COURSE SERIES
Course Number: BIOT 5219
Department: Biotechnology (BIOT)
CRN: 19988, 17204, 13246, 20118
Liz Frey is an accomplished professional in the pharmaceutical industry, currently serving as Director, Global Commercial Lead for Stroke and Neuropathic Pain at Biogen. With a strong focus on neurology and acute care products, Liz excels in developing go-to-market strategies and brand planning. She has a proven track record of high performance and expanded responsibilities, earning promotions throughout her career. Liz’s expertise lies in product management, market research, and strategic planning. She holds an MBA from Duke University and a Bachelor’s degree in Economics and English Literature from Northwestern University. In her free time, Liz enjoys reading, traveling, photography, skiing, and volunteering at a local animal shelter.
Eduardo Sanchez is an accomplished scientist with expertise in clinical CLIA/CAP/GCP settings. As a Clinical General Supervisor and Project Manager at Northeastern University’s Life Sciences Testing Center, he leads projects, optimizes processes, and coordinates collaborations. Eduardo excels in business development, client interfacing, and technical writing. His skills include cost-benefit analysis, laboratory workflow optimization, and validation of clinical methods. He has managed NGS sequencing projects, developed pooling methods for COVID-19 testing, and worked with regulatory agencies. Eduardo’s statistical data analysis, visualization, and clinical testing abilities are exceptional. With a Master’s in Biotechnology and a Bachelor’s in Chemistry, Eduardo’s proficiency in software tools and fluency in English and Spanish further enhance his contributions.
Robert E. Schultz is a dynamic and intellectually curious professional with a wealth of experience in the life science industries. With a background as an entrepreneur and sales/marketing executive, Robert has demonstrated his expertise in various domains, including pharmaceuticals, medical devices, digital health, and eCommerce. Alongside his professional career, Robert has also excelled in academia as an adjunct professor, teaching courses in marketing, entrepreneurship, healthcare innovation, and management information systems. He has a deep understanding of pedagogical methods and has leveraged learning management systems to enhance student experiences. As the founder of Massnex LLC and Tunza, Robert has successfully driven business growth and developed innovative solutions in the healthcare sector. His passion for bridging academia, industry, government, and philanthropy has made him a respected thought leader in the field. With an MBA in International Business and a BS in International Business with a specialization in Marketing, Robert brings a diverse skill set and a global perspective to his endeavors.
Youngbin Tak is a highly accomplished professional with extensive experience in the biotechnology industry. Holding an MBA with a concentration in Innovation and Entrepreneurship from Boston University Questrom School of Business, Youngbin has excelled in project management and strategic alliances. With a background in biotechnology and biochemistry, he has made significant contributions in drug discovery research and platform biology. Youngbin has worked in reputable organizations such as PineTree Therapeutics, Ultragenyx Pharmaceutical, AstraZeneca, Sanofi Genzyme, and CureMeta. He has a proven track record of implementing novel assays, managing multidisciplinary project teams, and advancing therapeutic initiatives. Youngbin is detail-oriented, a great problem solver, and possesses excellent oral and written communication skills.